Luminate: Phase IIb data

The double-blind, U.S. Phase IIb DEL MAR trial in 136 DME patients showed that once-monthly 1 mg Luminate met the primary endpoint of non-inferiority

Read the full 247 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE